CENTERS FOR DISEASE CONTROL



MORBIDITY AND MORTALITY WEEKLY REPORT

- 477 Rubella Vaccination During Pregnancy – United States, 1971-1981
- 481 Cholera, 1981
- 488 State Action to Prevent Motor Vehicle Deaths and Injuries among Children and Adolescents
- 491 Subscription to MMWR

Countdown toward the elimination of measles in the United States

Year	Week 35	Weeks 1-35		
1982	4	1,188		
1981	7	2,562		
1970	157	39,365		
1960	1,234	399,852		

١

Current Trends

Rubella Vaccination During Pregnancy - United States, 1971-1981

Since 1971, CDC has maintained a register of women who received rubella vaccine within the 3 months before or after conception, and who were prospectively followed to quantitate the risk of fetal abnormalities following exposure to the vaccine.

From January 1971 to December 1981, 730 pregnant women who received rubella vaccine either within 3 months before or within 3 months after their presumed dates of conception were reported to CDC. Five hundred thirty-eight of these women received either Cendehill* or HPV-77[†] vaccines; 189 received RA $27/3^{\$}$ vaccine, and three received rubella vaccine of an unknown type. At the time of vaccination, 215 women (29%) were known susceptible to rubella (no detectable rubella-specific antibodies); 42 (6%) were immune (presence of detectable rubella-specific antibodies), and 473 (65%) were of unknown immune status.

Exposure to Cendehill and HPV-77 vaccines (HPV-77:DE-5 and HPV-77:DK-12): The outcome of conception (live birth, stillbirth, spontaneous or induced abortion) was known for 500 of the 538 recipients of Cendehill or HPV-77 vaccines. Two hundred ninety (58%) of the vaccinees had full-term pregnancies (Table 1). None of the newborns had abnormalities com-

*Distribution discontinued in the United States in December 1976

[†]Distribution discontinued in the United States in January 1979

[§]Distribution begun in the United States in January 1979

Rubella - Continued

patible with congenital rubella syndrome (CRS)[¶]. Eight infants born to susceptible mothers or to mothers whose immune status was unknown showed evidence of infection by detection of rubella-specific IgM in cord blood, by the persistence of rubella-specific hemagglutination inhibition (HI) antibodies beyond 6 months of age, or by the isolation of rubella virus. All eight children, who are now 2 to 7 years of age, are growing and developing normally with no demonstrated signs or symptoms of CRS.

Rubella virus was isolated from the products of conception in 17 of 85 (20%) susceptible women who had received Cendehill or HPV-77 vaccines and who elected to have abortions. Six spontaneous abortions were reported among the 100 susceptible women who had received these vaccines and whose pregnancies proceeded without intervention.

The dates of vaccination and the estimated dates of conception (DOC) were available for 87 of the 94 susceptible women who had full-term pregnancies (Figure 1). Of these, 33 (38%) were vaccinated within 1 week before to 4 weeks after conception. All women who carried their pregnancies to term gave birth to infants who did not have any malformations compatible with the CRS, regardless of interval between vaccination and conception.

Exposure to RA 27/3 vaccine: The outcome of pregnancy was known for 177 of the 189 recipients of the RA 27/3 vaccine. One hundred fifty-three (86%) of the vaccinees had full-term pregnancies (Table 2). None of the resulting newborns had abnormalities compatible with CRS. Serologic evaluation (rubella HI titers and specific IgM on cord or neonatal blood specimens) was performed for 44 of the 49 infants whose mothers were susceptible, and for 76 of the 89 infants whose mothers were of unknown immune status. One infant born to a susceptible woman had a rubella-specific IgM antibody titer of 8 in the cord blood. Both mother and infant had HI titers of 128 at the time of birth; the infant's HI titer decreased to 16 at 2 months of age. The infant had no evidence of malformations either at birth or at the 6 month followup examination.

Rubella virus was isolated from the products of conception in only 1 of 25 (4%) susceptible women studied who had received RA 27/3 vaccine within 3 months of conception (12 cases

 \P Defined as any two complications listed in A or 1 from A and 1 from B

Prevaccination immunity status	Total cases	Live births		Spontane and s	Induced abortions		Outcome unknown		
		No.	%	No.	%	No.	%	No.	%
Susceptible	149	94	17.5	6	1.1	43	8.0	6	1.1
Immune	25	22	4.1	0	_	3	0.5	0	_
Unknown	364	174	32.3	18	3.4	140	26.0	32	6.0
TOTAL	538	290	53.9	24	4.5	186	34.5	38	7.1

TABLE 1. Pregnancy outcom	nes for 538	recipients of	f Cendehill or	HPV-77 va	ccine –
United States, through Decen	ber 31, 198	1*			

*No women entered on the register during 1981 were vaccinated with Cendehill or HPV-77 vaccine.

A. Cataracts/congenital glaucoma (either or both count as 1), congenital heart disease, loss of hearing, pigmentary retinopathy.

B. Purpura, splenomegaly, jaundice (with onset beginning 24 hours after birth), microcephaly, mental retardation, meningoencephalitis, radiolucent bone disease.

Rubella -- Continued

reported to CDC and 13 from the literature) (1-3). No spontaneous abortions were reported among the 49 susceptible women who had received RA 27/3 vaccine and whose pregnancies proceeded without intervention.


The dates of vaccination and estimated DOC were available for all of the 49 susceptible women who had full-term pregnancies (Figure 1). Twenty-one women (43%) were vaccinated within 1 week before to 4 weeks after conception. All women who had full-term pregnancies gave birth to infants who had no malformations compatible with CRS, regardless of interval between vaccination and conception.

Reported by Immunization Div, Center for Prevention Svcs, CDC.

Editorial Note: Since the licensure of live rubella virus vaccine in 1969, there has been concern that the attenuated vaccine virus poses teratogenic risks to the fetuses of pregnant recipients. A CDC register was set up to evaluate the risk; from that register, data are obtained through reports from physicians and state and local health departments, as well as directly from women vaccinated either within 3 months before or 3 months after conception. The patients are followed prospectively to determine the outcomes of the pregnancies.

During the highest risk period for viremia and fetal defects (1 week before to 4 weeks after conception) (4,5), 54 of the 143 (38%) susceptible mothers were vaccinated with one of the four vaccines. Neither these infants nor any of the others were born with CRS; therefore, the ob-

FIGURE 1. Rubella vaccination of susceptible women, by estimated date of conception (DOC)* and vaccine type, 1971-1981



*DOC estimated to be 14 days after first day of last menstrual period.

Rubella - Continued

served CRS risk to date is zero. The theoretical maximum risk for the occurrence of CRS in this group of children, based on the 95% confidence limits of the binomial distribution, may be as high as 3%. This overall maximum theoretical risk is far less than the 20% or greater risk associated with maternal infection with wild rubella virus during the first trimester of pregnancy (6).

In 1979, when RA 27/3 rubella vaccine replaced the other rubella vaccines, concern was raised that it might be more teratogenic than earlier rubella vaccines. Data from the CDC-maintained register thus far show no evidence that the RA 27/3 vaccine can cause defects compatible with CRS.

The 4% rubella virus isolation rate from products of conception for RA 27/3 vaccine is substantially lower than the 20% rate for the Cendehill and HPV-77 vaccines. Although limited, these data suggest there is probably no greater risk of placental or fetal infection from RA 27/3 vaccine than from Cendehill or HPV-77 vaccines (7).

Based on an earlier review of the data, the Immunization Practices Advisory Committee (ACIP) has stated that the risk of CRS following vaccination within 3 months of conception is so small as to be negligible (8). The additional data collected in 1981 support this statement. Rubella vaccination of a pregnant female should not in itself indicate abortion. A final decision, however, should rest with the patient and her physician.

Nevertheless, rubella vaccine should not be administered to pregnant females. Reasonable precautions before administering rubella vaccine to women of childbearing age include determining whether females are pregnant and excluding those who are. Non-pregnant women are advised not to become pregnant for 3 months after vaccination.

CDC encourages the reporting of all cases of rubella vaccination occurring within 3 months of conception so that the risks involved may be more completely defined for the presently licensed RA 27/3 vaccine. Laboratory services for serologic determination and for culture of abortion specimens are available at CDC for women who are entered on the register. Immunization Division personnel are available to discuss individual situations in detail. *References*

- 1. Banatvala JE, O'Shea S, Best JM, Nicholls MV, Cooper K. Transmission of RA27/3 rubella vaccine strain to products of conception (letter). Lancet 1981;1:392.
- 2. Furukawa T, Miyata T, Kondo K, Kuno K, Isomura S, Takekoshi T. Clinical trials of RA 27/3 (Wistar) rubella vaccine in Japan. Am J Dis Child 1969;118:262-3.
- 3. Bernstein DI, Ogra PL. Fetomaternal aspects of immunization with RA27/3 live attenuated rubella virus vaccine during pregnancy. J Pediatr 1980;97:467-70.
- O'Shea S, Parsons G, Best JM, Banatvala JE, Balfour HH Jr. How well do low levels of rubella antibody protect? (letter) Lancet 1981;2:1284.

cember 31, 1981					
Prevaccination	Total	Live	Spontaneous abortions	Induced	Outcome
immunitystatus	cases	births	and stillbirths	abortions	unknown

TABLE 2. Pregnancy outcomes for 189 recipients of RA27/3 vaccine — through December 31, 1981

immunity status	cases	b	irths	and st	tillbirths	abor	tions	unkn	own
		No.	%	No.	%	No.	%	No.	%
Susceptible	65	49	25.9	0	-	10	5.3	6	3.2
Immune	16	15	7.9	0	_	0	_	1	0.5
Unknown	108	89	47.1	2	1.1	12	6.3	5	2.7
TOTAL	189	153	80.9	2	1.1	22	11.6	12	6.4

480

Vol. 31/No. 35

)

Rubella - Continued

MMWR

- Balfour HH Jr, Groth KE, Edelman CK, Amren DP, Best JM, Banatvala JE. Rubella viraemia and antibody responses after rubella vaccination and reimmunisation. Lancet 1981;1:1078-80.
- 6. Dudgeon JA. Congenital rubella. Pathogenesis and immunology. Am J Dis Child 1969; 118:35-44.
- 7. Preblud SR, Stetler HC, Frank JA Jr, Greaves WL, Hinman AR, Herrmann KL. Fetal risk associated with rubella vaccine. JAMA 1981;246:1413-7.
- 8. ACIP. Rubella prevention. MMWR 1981;30:37-42, 47.

International Notes

Cholera, 1981

As of April 5, 1982, a provisional total of 36,840 cholera cases had been reported worldwide for 1981, as compared with 42,614 in 1980. Altogether, 34 countries were infected, the same number as in 1980, and an additional eight countries reported only imported cases (Table 3). Only one new country was infected.

TABLE 3. Cases of cholera reported to	WHO,	1981
---------------------------------------	------	------

Countries and areas	Total	Countries and areas	Total
AFRICA		ASIA (Cont'd)	
Benin	2	Jordon	870
Burundi*	468	Kuwait	8†
Cameroon, United Republic of*	209	Malaysia	469
Gabon	2	Nepal	24
Kenya	2,424	Pakistan	4
Liberia	1,477	Philippines*	150
Mozambique	1,753	Saudi Arabia	13 (4 [†])
Niger	7†	Singapore	34 (2 [†])
Nigeria	107	Sri Lanka	574
Rwanda	20	Thailand	39
South Africa	4,180	Viet Nam	157
Swaziland	238	West Bank	7 (2 [†])
Tanzania, United Republic of	4,241		
Zaire	2,379	TOTAL	19,255 (33 [†])
Zambia	14		
TOTAL	17,521 (7 [†])	EUROPE	
		Austria	2 [†]
AMERICA	21 (4 [†])	France	20 (19 [†])
United States of America	21 (41)	Germany, Federal Republic of	4†
	21 (4 [†])	Netherlands	2†
TOTAL	21 (4.)	Poland	2 [†] 1 [†]
ASIA		United Kingdom	12 [†]
Burma	28		
Gaza Strip	161	TOTAL	41 (40 [†])
Hong Kong	3†		
India	4.681	OCEANIA	
Indonesia*	5,980	Australia	2
Iran	6,034		-
Japan	19 (14 [†])	TOTAL	2

*incomplete figures

[†]imported cases

Cholera – Continued

In Africa, the total number of countries with cholera declined from 16 in 1980 to 14 in 1981. A total of 17,521 cases were reported, as compared with 18,731 in 1980. However, the disease appeared to be more widespread in countries in southeastern Africa, and Swaziland reported infection for the first time during the present pandemic.

Seventeen countries in Asia reported cholera infection in 1981, as compared with 15 in 1980; the total number of cases was 19,255 (23,851 in 1980). There was a noticeable recrudescence of cholera in the Eastern Mediterranean area where six countries were infected, four more than in the previous year; the most severely affected were Iran and Jordan.

Cholera was again observed on the Gulf Coast of the United States, where 19 cases occurred, including an outbreak of 17 cases among employees of an oil rig in the coastal region of Texas. The outbreak was considered due to contamination of unchlorinated drinking water with drilling water and sewage containing *V. cholerae* 01 shed by the index case; the source of infection for the index case could not be determined. All the strains from the 31 cases occurring along the Gulf Coast since 1973 appear to be essentially identical, suggesting that the toxigenic *V. cholerae* 01 has persisted in this region for at least the last 8 years.

Oceania remained free of cholera in 1981, with the exception of two cases in Australia (at Lismore in New South Wales).

Apart from one isolated case in France, no indigenous cases were reported from Europe. There was, however, a significantly larger number of imported cases than in previous years. *Reported by WHO Weekly Epidemiologic Record* 1982;57:131.

		35th Week End	ng	Cumulative, First 35 Weeks			
Disease	September 4, 1982	September 5, 1981	Median 1977-1981	September 4, 1982	September 5, 1981	Median 1977-198	
Aseptic meningitis	266	465	372	4,490	5,242	3,902	
Brucellosis	2	8	1	104	103	117	
Encephalitis: Primary (arthropod-borne							
& unspec.)	36	55	54	703	770	596	
Post-infectious	-	-	2	49	66	150	
Gonorrhea: Civilian	15,505	21,407	20,833	628,537	671,094	659,399	
Millitary	402	701	631	16,707	19,585	18,272	
Hepatitis: Type A	281	453	540	14,503	16,983	19,190	
Type B	302	384	337	13,868	13,679	11,102	
Non A. Non B	21	N	N	1,428	N	N	
Unspecified	137	210	206	5,956	7,323	6,731	
Legionellosis	14	N	N	316	N	N	
Leprosy	4	1	5	132	176	115	
Malaria	24	28	25	680	967	499	
Measles (rubeola)	4	7	68	1.188	2,562	12,789	
Meningococcal infections: Total	44	39	32	2.096	2,535	1,930	
Civilian	44	39	32	2.084	2.526	1,914	
Military				12	-/9	14	
Mumps	16	23	65	4.096	3,155	11.049	
Pertussis	58	31	32	938	803	935	
Rubella (German measles)	8	18	44	1.965	1.724	10,606	
Syphilis (Primary & Secondary): Civilian	445	703	513	21.796	20.357	16,210	
Military	9	10	9	281	250	206	
Tuberculosis	317	541	541	16.969	17.943	18.673	
Tularemia	9	12	9	159	168	139	
Typhoid fever	9	5	14	264	344	320	
Typhus fever, tick-borne (RMSF)	36	44	44	792	987	886	
Rabies, animal	98	136	86	4,220	5,192	3,408	

TABLE I. Summary-cases of specified notifiable diseases, United States

TABLE II. Notifiable diseases of low frequency, United States

	Cum. 1982		Cum. 1982
Anthrax Botulism Cholera Congenital rubella syndrome Diphtheria Leptospirosis (Ark. 1, Tex. 3) Plague (Oreg. 1)	- 54 - 5 2 38 11	Poliomyelitis: Total Paralytic Psittacosis Rabies, human Tetanus (La. 1) Trichinosis (Ohio 2, Mich. 1) Typhus fever, flea-borne (endemic, murine)	3 3 84 54 69 24

482

September 4, 1982 and September 5, 1981 (35th week)												
	Aseptic		Encep	halitis			H	lepatitis (V	/iral), by ty	pe	Legionel-	
Reporting Area	Menin- gitis	Brucel- losis	Primary	Post-in- fectious	Gono (Civi	ilian)	A	В	NA,NB	Unspeci- fied	losis	Leprosy
hoponing , nee	1982	Cum. 1982	Cum. 1982	Cum. 1982	Cum. 1982	Cum. 1981	1982	1982	1982	1982	1982	Cum. 1982
UNITED STATES	266	104	703	49	628,537	671,094	281	302	21	137	14	132
NEW ENGLAND	15	3	31	5	15,282	16,626	3	16	-	14	1	1
Maine	1	-	-	-	772	860 597	1	2 1	-	1	1	-
N.H. Vt.	2	-	5	-	448 289	277	1		-		-	-
Mass.	4	-	12	-	6,932	6,977	1	5	-	13	-	-
R.I.	3	3	14	1 4	1,041 5,800	925 6,990	-	17	-	-	-	1
Conn.	5	3	14						_		-	
MID. ATLANTIC	27	3	76	13 3	78,865 13,052	79,720 13,212	28 5	75 9	7	14	5	4
Upstate N.Y. N.Y. City	13 4	3	25 14	-	32,776	33,055	16	49	-	7	-	1
N.J.	7	-	13	-	14,109	15,438		17		6 U	- 5	1
Pa.	3	-	24	10	18,928	18,015	υ	U	U	U	5	
E.N. CENTRAL	56	1	155	10	85,076	101,080	71	42	-	11	1	3
Ohio	27	1	62	4	24,581	32,328 8,650	25 22	11 9	:	3 4	1	-
Ind. III.	6	-	33 9	3 1	10,812 19,607	28,894	5	4	-	-	-	3
Mich.	23	-	46	-	21,806	22,023	19	18	-	4	-	-
Wis.	-	-	5	2	8,270	9,185	-	-	-	-	-	-
W.N. CENTRAL	13	14	56	3	29,868	31,657	18	7	1	4	4	3
Minn.	-	1	20	1	4,314	4,846 3,478	2	1	1	1	1	1
lowa Mo.	3 2	3 4	23 6	1	3,133 14,235	14,655	6	-	-	3	ĩ	1
N. Dak.	-	-	-	-	400	415	-	-	-	-	-	1
S. Dak.		1	4	1	825	877 2.436	1	1 2	-	-	-	
Nebr. Kans	4	2	4	-	1,836 5,125	4,950	-	3	-	-	-	-
		-		-		100.054	62	100	5	19	1	9
S. ATLANTIC Del.	72	20	112	7	165,225 2,666	166,254 2,676	1	2		-	-	-
Md.	5	-	17	-	21,086	19,090	3	24	1	1	-	3
D.C.		7	23	ī	9,321 13,127	9,620 15,250	-	1 15		1	-	1
Va. W. Va.	15 1	<u>'</u>	23	-	1,857	2,503	4	-	-	-	-	-
N.C.	15	-	13	1	26,565	25,622	5	.7	1	3 4	-	-
S.C. Ga.	1 13	2	8	-	16,178 30,544	16,143 34,665	13 8	10 12	1	1	-	1
Fla.	22	10	44	5	43,881	40,685	28	29	2	9	1	4
E.S. CENTRAL	7	11	36	2	55,273	56,189	9	13	1	-	-	-
Ky.	2	-	-	-	7,484	6,954	4	2	-	-	-	-
Tenn.	4	6 4	16	2	21,681 16,389	21,227 17,261	2 1	5 4	1	-	-	-
Ala. Miss.	1	1	15 5	-	9,719	10,747	2	2	-	-	-	-
				1	00.05.0	00 100			4	70	1	22
W.S. CENTRAL Ark.	41 7	28 5	113 8		88,352 7,264	88,129 6,594	71	31	4	70	-	-
La.	3	6	14	-	16,597	15,177	10	10	1	1	:	-
Okla. Tex	3 28	4 13	18 73	ī	9,711 54,780	9,583 56,775	3 56	3 17	3	2 60	1	22
		13										
MOUNTAIN	17	-	20	3	21,510	26,117	13	14	2	3	-	2
Mont. Idaho	1	-	-		876 993	947 1,165	1	-	-	-	-	1
Wyo.	-	-	-	-	629	606	-		-	-	-	-
Colo. N. Mex.	5	-	10	1	5,866 2,790	7,098	7	6	1	1	-	
Ariz.	ΰ	-	6	:	2,790	2,789 7,836	2 U	Ū	ບໍ່	Ű	Ū	-
Utah	10	-	-	2	1,032	1,264	-	1	-	-	-	1
Nev.	-	-	4	-	3,669	4,412	1	7	-	2	-	-
PACIFIC	18	24	104	5	89,086	105,322	6	4	1	2	1	88
Wash. Oreg	5	1	10	-	7,516	8,754	-	2	:	2	1	7
Oreg. Calif.	Ū	22	3 87	- 5	5,223 72,355	6,185 85,678	6 U	1 U	1 U	Ū	Ū	58
Alaska	9	-1	3	-	2,253	2,635	-	3	-	-	-	1
Hawaii	4	-	1	-	1,739	2,070	-	-	-	-	-	21
Guam	Ų	-	-	-	85	79	U	υ	U	Ų	U	-
P.R. V.I.	2 U	-	1	-	1,924	2,209	15	15	- U	9 U	Ū	-
Pac. Trust Terr.	Ŭ	-	:	•	148 245	139 305	U U	U U	Ű	Ŭ	ŭ	12

TABLE III. Cases of specified notifiable diseases, United States, weeks ending September 4, 1982 and September 5, 1981 (35th week)

N: Not notifiable

)

)

U: Unavailable

Meningococcal Malaria Measles (Rubeola) Infections Mumps Pertussis Rubella Reporting Area (Total) Cum Cum. Cum. Cum. Cum. Cum. Cum. UNITED STATES 1.188 2.562 2,096 4.096 1,965 1.724 NEW ENGLAND Maine N.H. . Vt. . Mass. ā . -R.I. --Conn. . . MID. ATLANTIC Upstate N.Y. . N.Y. City _ . N.J _ Pa. . -E.N. CENTRAL 2.152 . Ohio ž -1,556 . Ind. . . -ш . Mich. ŝ -. Wis. -. W.N. CENTRAL ---Minn _ -. --lowa -. --Mo --. . . N. Dak _ -_ S. Dak -. -. -. Nebr. -Kans. -..... . --. S. ATLANTIC Del. A -. Md. --D.C. . Va. _ . W. Va. _ -N.C. ŝ ž â -S.C. . ā --Ř Ga. . -з Fla . _ . E.S. CENTRAL з . Ky. -. . Tenn. -з -Ala. ž . . Miss. -ě W.S. CENTRAL Ark. -. . . La. -. _ • Okla Tex. -MOUNTAIN . --Mont. . -Idaho . • з -. . -Wyo. . . Colo. • . -. N. Mex. -Ariz. υ υ U υ υ υ Utah . Nev . . . PACIFIC -. 1,339 Wash -. Oreg. Calif υ U υ υ υ υ 1,283 Alaska . -Hawaii . . . Guam υ υ υ U з υ PR υ ī VI υ ū υ --U υ u Pac. Trust Terr. Ū Ũ . -u u υ u _

TABLE III. (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending September 4, 1982 and September 5, 1981 (35th week)

U: Unavailable

)

MMWR

TABLE III. (Cont.'d). Cases of specified notifiable diseases, United States, weeks ending September 4, 1982 and September 5, 1981 (35th week)

Perperting Area	Syphilis (Primary &	(Civilian) Secondary)	Tuber	culosis	Tula- remia	Typhoid Fever		(Tick-	s Fever borne) MSF)	Rabies, Animal
Reporting Area	Cum. 1982	Cum. 1981	1982	Cum. 1982	Cum. 1982	1982	Cum. 1982	1982	Cum. 1982	Cum. 1982
JNITED STATES	21,796	20,357	317	16,969	159	9	264	36	792	4,220
EW ENGLAND	371	408	10	462	4		16	-	8	33
Aaine	3	4	2	40	-	-	-	-	:	24
I.H.	1	12	-	15	-	-	2	-	1	-
/t.	1	13	4	10 299	4	:	12	-	4	5
Mass. R.I.	248 19	266 24	4	19	-		12	-	2	
Conn.	99	89	3	79	-	-	2	-	ī	4
ID. ATLANTIC	3,025	2,979	56	2,854	7	5	44	-	28	128
Jpstate N.Y.	304	279	13	497	7	-	6 23	-	9 1	62
Y. City	1,811	1,776	32	1,103 559	-	- 5	23	-	12	8
N.J. Pa.	415 495	414 510	11 U	559 695	:	5	4	-	6	58
N. CENTRAL	1,147	1,473	74	2,626	1	1	22	2	76	455
Dhio	197	196	10	446	-	i	11	2	71	65
nd.	134	168	6	328	-	-	-	-	-	66
N.	538	787	32	1,089	-	-	3	-	5	238
Mich.	211	255	23	622	-	-	7	-	-	4
Nis.	67	67	3	141	1	-	1	-	-	82
W.N. CENTRAL	379	423	7	501	24	1	10 5	5	30	926 164
Minn.	76	145	-	87 54	2	-	1	-	Å	297
owa Mo.	21 226	16 228	6	242	16	1	ż	1	10	88
vio. N. Dak.	220	228		242	10		-			79
S. Dak.	í	ź	1	21	1	-	-	-	4	71
lebr.	11	5	-	20	2	-	1	1	2	104
lans.	37	20	-	68	2 3	-	1	3	10	123
. ATLANTIC	5,990	5,391	59	3,493	10	-	34	19	436	755
)el.	11	10	-	33	-	-	-	-	43	2 35
Ad.	333	400	15	404	1	-	9	-	43	35
D.C.	331	427	1	140 387	2	-	2	7	69	384
/a. N. Va.	408 21	471 16	4	106	2	-	3		7	37
N.C.	476	413	10	550	-	-	ĩ	6	185	55
S.C.	354	352	ž	315	6	-	3	4	94	43
Ga.	1.231	1,380	-	532	-	-	-	2	36	145
la.	2,825	1,922	20	1,026	1	-	16	-	2	54
E.S. CENTRAL	1,518	1,355	55	1,575	6	-	14	4	68	498
Ky.	80	74	15	415		-	:	:	1	102
lenn.	411	499	21	508	4	:	2 9	4	45 10	283 108
Ala. Viss.	568 459	391 391	9 10	438 214	2	-	3	-	12	5
				2.054	82	2	27	5	131	806
W.S. CENTRAL Ark.	5,688	4,944 110	47 5	2,054	51		- 3	5	22	108
La.	142 1,296	1,138	16	325	3	-	3	-		27
Okla.	119	113		253	24	-	2	3	68	148
Tex.	4,131	3,583	26	1,251	4	2	19	2	41	523
OUNTAIN	558	523	5	460	19	-	11	1	10	191
Mont.	3	11	-	27	2	-	-	1	3	67
daho	24	17	-	23	1	-	-	-	2	.8
Nyo.	15	. 7	-	2	2	-	-	-	1	17 34
Colo.	155	159	-	50 87	3 1		3	-	1	34 15
N. Mex. Ariz.	137 119	93 123	1 U	87 197	-	U U	5	Ū		35
Anz. Jtah	119	21	-	25	10		2	-		12
Vev.	90	92	4	49	-	-	1	-	2	3
PACIFIC	3,120	2,861	4	2,944	6	-	86	-	5	428
Wash.	100	117	3	186	ĩ	-	3	-	-	4
Oreg.	77	63	-	119	-	•	3	-	1	2
Calif.	2,856	2,625	U	2,375	4	U	77	U	4	345
Alaska Hawaii	8 79	10 46	1	65 199	1	•	1 2	-		77
			-				_			_
Guam P.R.	1 465	449	U	34 254	-	U	2	U	-	36
r.n. V.1.	405	13	Ū	254	-	Ū		Ū	-	-
							-			

U: Unavailable

All Causes, By Age (Years) All Causes, By Age (Years) P&I** P&I* **Reporting Area Reporting Area** ΔII ΔH Total Total <1 <1 ≥65 45-64 25-44 1-24 ≥65 45-64 25-44 1-24 Ages Ages NEW ENGLAND S ATLANTIC 1.110 Boston Mass Atlanta, Ga. Bridgeport, Conn. ž Baltimore, Md Cambridge, Mass. Charlotte, N.C. з Fall River, Mass. Jacksonville, Fla _ Ā Hartford, Conn. Miami, Fla Lowell, Mass. ĩ Norfolk, Va з Lynn, Mass. ŝ Richmond, Va . New Bedford, Mass. Savannah, Ga New Haven, Conn. St. Petersburg, Fla з Providence, R.I. ŝ i Tampa, Fla. Somerville, Mass Washington, D.C. Springfield, Mass. ġ Wilmington, Del. Waterbury, Conn. Worcester, Mass E.S. CENTRAL Birmingham, Ala, MID. ATLANTIC 2,352 1,540 Chattanooga, Tenn. ż Δ Albany, N.Y. Knoxville, Tenn, ğ Allentown, Pa Louisville, Ky. ā Buffalo, N.Y. Memphis, Tenn. Camden N.J Mobile, Ala. Elizabeth, N.J. -Montgomery, Ala. ġ Erie, Pa.t Nashville, Tenn. Jersey City, N.J. ā N.Y. City, N.Y. 1 288 W.S. CENTRAL 1.249 Newark, N.J. Austin, Tex. Paterson, N.J. Baton Rouge, La Philadelphia, Pa.t Corpus Christi, Tex. 1 Pittsburgh, Pa.† Dallas, Tex. Reading, Pa. El Paso, Tex Rochester, N.Y з Fort Worth, Tex. Schenectady, N.Y. Houston, Tex. Scranton Pat Little Rock, Ark Λ Svracuse, N.Y New Orleans, La Trenton, N.J. San Antonio, Tex -Utica, N.Y. Shreveport, La. Δ Yonkers, N.Y. Tulsa, Okla. E.N. CENTRAL 2.064 1,292 MOUNTAIN Akron, Ohio Albuquerque, N.Mex. Canton, Ohio Colo. Springs, Colo. Chicago, III Denver Colo Cincinnati, Ohio Las Vegas, Nev. з Cleveland, Ohio Ogden, Utah з Columbus, Ohio Phoenix, Ariz. Dayton, Ohio Pueblo Colo Detroit, Mich. Salt Lake City, Utah Evansville, Ind. Tucson, Ariz. Fort Wayne, Ind. Gary, Ind. § PACIFIC 1,807 1,140 Grand Rapids, Mich. Berkeley, Calif Indianapolis, Ind. Δ Fresno, Calif. Madison, Wis. Glendale, Calif з Milwaukee, Wis Honolulu, Hawai з Peoria, III. ž Long Beach, Calif. Rockford, III. § Los Angeles, Calif. South Bend, Ind. Oakland, Calif Toledo, Ohio Pasadena, Calif -Youngstown, Ohio Portland, Oreg Sacramento, Calif W.N. CENTRAL San Diego, Calif. Des Moines, Iowa § San Francisco, Calif Duluth, Minn. San Jose, Calif. Kansas City, Kans. Seattle, Wash. Kansas City, Mo. Spokane, Wash. 28 Lincoln, Nebr Tacoma, Wash. Minneapolis, Minn. 11,183 Omaha, Nebr. TOTAL 6.944 2.631 Δ St. Louis, Mo. St. Paul, Minn. Wichita, Kans.

TABLE IV. Deaths in 121 U.S. cities,* week ending September 4, 1982 (35th week)

 Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

** Pneumonia and influenza

† Because of changes in reporting methods in these 4 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

tt Total includes unknown ages.

§ Data not available. Figures are estimates based on average of past 4 weeks.

Cause of	Years of potential life lost before		ated mortality oril 1982	Estimated number of physician contacts April 1982 ⁴	
morbidity or mortality (Ninth Revision ICD, 1975)	age 65 by persons dying in 1980 ¹	Number ²	Annual Rate/100,000 ³		
ALL CAUSES (TOTAL)	10,006,060	170,860	899.9	97,736,000	
Accidents and adverse effects (E800-E807, E810-E825, E826-E949)	2,684,850	7,560	39.8	5,131,000	
Malignant neoplasms (140-208)	1,804,120	36,320	191.3	2,368,000	
Diseases of heart (390-398, 402, 404-429)	1,636,510	67,310	354.5	5,485,000	
Suicides, homicides (E950-E978)	1,401,880	4,160	21.9	_	
Chronic liver disease and cirrhosis (571)	301,070	2,350	12.4	142,000	
Cerebrovascular diseases (430-438)	280,430	13,480	71.0	543,000	
Pneumonia and influenza (480-487)	124,830	4,580	24.1	1,166,000	
Diabetes mellitus (250)	117,340	2,720	14.3	2,768,000	
Chronic obstructive pulmonary diseases and allied conditions					
(490-496)	110,530	5,700	30.0	1,920,000	
Prenatal care ⁵				2,340,000	
Infant mortality ⁵		3,500	11.9 /1,000	live births	

TABLE V. Years of potential life lost, deaths, and death rates, by cause of death, and estimated number of physician contacts, by principal diagnosis, United States

¹Years of potential life lost for persons between 1 year and 65 years old at the time of death are derived from the number of deaths in each age category as reported by the National Center for Health Statistics, *Monthly Vital Statistics Report* (MVSR), Vol. 29, No. 13, September 17, 1981, multiplied by the difference between 65 years and the age at the mid-point of each category. As a measure of mortality, "Years of potential life lost" underestimates the importance of diseases that contribute to death without being the underlying cause of death.

²The number of deaths is estimated by CDC by multiplying the estimated annual mortality rates (MVSR Vol. 31, No. 5, August 12, 1982, pp. 8-9) and the provisional U.S. population in that month (MVSR Vol. 31, No. 4, July 14, 1982, p.1) and dividing by the days in the month as a proportion of the days in the year.

³Annual mortality rates are estimated by NCHS (MVSR Vol. 31, No. 5, August 12, 1982, pp. 8-9), using the underlying cause of death from a systematic sample of 10% of death certificates received in state vital statistics offices during the month and the provisional population of those states included in the sample for that month.

⁴IMS America *National Disease and Therapeutic Index* (NDTI), Monthly Report, April 1982, Section III. This estimate comprises the number of office, hospital, and nursing home visits and telephone calls prompted by each medical condition based on a stratified random sample of office-based physicians (2,100) who record all private patient contacts for 2 consecutive days each quarter.

⁵"Prenatal care" (NDTI) and "Infant mortality" (MVSR Vol. 31, No. 4, July 14, 1982, p.1) are included in the table because "Years of potential life lost" does not reflect deaths of children <1 year.

Perspectives in Disease Prevention and Health Promotion

State Action to Prevent Motor Vehicle Deaths and Injuries among Children and Adolescents

Motor vehicle fatalities (MVF) are the leading cause of lost years of potential life, and in 1980, accounted for 54,200 deaths (1). The National Transportation Safety Board estimates that although fatalities on American highways decreased by 4% in 1981, reversing a 5-year upward trend, 145 persons, including 12 children, die each day in vehicular collisions (2).

Among children ages 1 to 14, motor vehicle collisions are a major cause of injury and disability and are responsible for 20% of all deaths in that age group. In 1980, approximately 90,000 children under 6 years of age and 800,000 children 6 to 16 years of age were injured by motor vehicles (3). Over half the MVF among 1 to 14 year-olds occur among pedestrians. Of the MVF among 15 to 19 year-olds, 25% involve the teenagers as passengers; in another 25%, teenaged drivers are killed (4).

In an effort to reduce motor vehicle accidents and deaths, states have begun passing legislation pertaining to child restraints, alcohol use, and other issues related to the prevention of motor vehicle deaths and injuries.

Child restraints : In response to statistics indicating that restrained children are 50% to 70% less fikely to be injured or killed in an auto accident than unrestrained children (5) and that back seat passengers are less likely to be injured than front seat passengers, 21 states have enacted laws requiring the use of, or have instituted public education programs on, safety seats or belts for children. Tennessee, which passed the first such law, requires parents of children under 4 years of age to use federally approved child restraint systems. The law became effective January 1, 1978, and active enforcement and public education campaigns have increased child restraint use in large metropolitan areas from 9% in 1977 to 32% in 1981. Injury rates in Tennessee among children under 4 years of age have decreased from 440.0 injuries per 100,000 children in 1979 to 306.1/100,000 in 1981, a 30% decrease, while death rates have decreased 55% from 7.72 deaths/100,000 children in 1979 to 3.5/100,000 in 1981 (*6*).

Sixteen of those 21 states, encompassing over 40% of the American population, have passed laws requiring parents to use car restraints for their children (7). Three (California, Indiana, and Maine) have passed laws requiring state agencies to conduct public information campaigns on the importance of child passenger safety. Hawaii has enacted a state income tax credit for purchase of a child safety restraint. In other states, child restraint legislation is pending.

To prevent motor vehicle deaths and injuries among adolescents and adults, many European countries as well as Australia, Canada, and New Zealand, have implemented mandatory, comprehensive safety belt use laws. In Victoria, Australia, safety belt use increased from approximately 15% to between 80% and 90% after enactment of legislation requiring use by all automobile occupants over age 8, and both MVF and injuries decreased. Although injuries have decreased among passengers under age 17, no decrease in fatalities has been noted (8). Statistics indicate that sustained enforcement and education are necessary to the continued use of restraints. In Ontario, Canada, belt use increased to 80% immediately after enactment of a safety belt use law, then decreased to 50%. When the law was actively enforced, use increased to 66% (9). In the United States, safety belt use by adolescents and adults can reduce fatalities by 50% and injuries by 65% (5). Michigan has introduced legislation requiring safety belts or passive restraints for all drivers and front-seat passengers.

Vol. 31/No. 35

Motor Vehicle Deaths - Continued

Alcohol use: Half of all deaths from motor vehicle crashes and one-third of accidents in which occupants receive serious injuries involve drivers with blood-alcohol concentrations of 0.10% or higher (10). Other drugs, either independently or in combination with alcohol, also contribute to vehicular accidents. Studies in England have found significant associations between use of minor tranquilizers and serious accidents (11). Consequently, several states have raised their legal drinking ages. In the mid-1970's, when Michigan lowered its legal drinking age to 18, both the number of establishments serving drinks and their hours of operation increased, as did the number of traffic accidents and MVF among 18 to 20 year-olds (12). In response to these findings, Michigan raised its legal drinking ages to 21. Connecticut, Maryland, and New York. among others, have also raised their legal drinking ages. In addition, citizens' groups have encouraged state legislatures to pass laws restricting night driving by teenagers, imposing mandatory license suspension for driving while intoxicated, and imposing stiffer penalties for convicted offenders.

Motorcycle helmets: By 1975, as a result of a federal requirement, all but three states had enacted laws requiring helmet use for motorcyclists. In 1976 the federal requirement was repealed, and by 1982, nine states had no helmet laws and 22 had amended theirs to require helmets only for teenaged riders (13). Between 1976 and 1980, deaths from motorcycle accidents increased by 49%. Motorcyclists have a 7-fold greater chance of fatal injury per mile driven than automobile drivers, (14). Over 30% of fatal motorcycle accidents occur among persons under 20 years of age (4). In a recent study conducted by the Minnesota Department of Health, in conjunction with the Minnesota Department of Public Safety, the effects of helmet use were analysed using 159 head injury cases from motorcycle accidents. The protective effects of helmets were evident at all levels of injury severity, and the degree of protection increased with severity; a non-helmeted rider was twice as likely to acquire a minor head injury as a helmeted rider and approximately five times as likely to acquire a severe or critical injury (15).

Education: Other approaches to preventing MVF among teenagers include raising the driving age and instituting comprehensive driver education programs. In Connecticut, a person can only obtain a drivers license before age 18 if he completes an approved driver education course; by eliminating state funding for driver education, Connecticut decreased the number of adolescent drivers and thus the number of 16 and 17 year-olds involved in accidents (*16*). Programs sponsored by community, professional, and government organizations have indicated the need for research concerning the effectiveness of driver education and the methods of preventing pedestrian injuries/fatalities.

Motor vehicle accidents result not only in morbidity and mortality but also in social and economic losses — health care costs, lost school time, lost work time for parents, rehabilitation costs, and the long-term effects of permanent disability on health, educational achievement, and quality of life. The prevention of vehicular-related injuries and deaths among children and adolescents requires a combination of strategies: designing roads and automobiles to prevent accidents, improving cars and safety seats to reduce the consequences of accidents, eliminating hazards to pedestrians, preventing alcohol and drug use by drivers, and advocating use of child restraints and safety belts.

Reported by the Office of Program Planning and Evaluation, Office of the Director, CDC.

References

- 1. National Center for Health Statistics. Annual summary of births, deaths, marriages, and divorces, 1980. In: Monthly vital statistics report, September 17, 1981; 29:21.
- 2. Transportation fatalities down in 1981. Journal of American Insurance 1982;58:5-6.
- National Center for Health Statistics. Current estimates from the National Health Interview Survey, United States, 1980. In: Vital and health statistics 1981; Series 10(139):21.

Motor Vehicle Deaths - Continued

- 4. National Center for Health Statistics. Vital statistics of the United States 1978; Il Mortality, Part A.
- The National Highway Traffic Safety Administration. Effectiveness and efficiency of safety belt and child restraint usage programs. Washington, D.C.: Department of Transportation, January 1982. (DOT-HS-806-142).
- 6. Tennessee Department of Public Health. Child Safety Program, unpublished data, 1982.
- National Safety Council. Policy update on child restraint laws. (Alabama, Connecticut, Delaware, Florida, Kansas, Kentucky, Massachusetts, Michigan, Minnesota, New York, Nebraska, North Carolina, Rhode Island, Virginia, West Virginia, and Wisconsin) August 1982.
- 8. McDermott F, Hough D. Vehicle-occupant fatalitites after legislation for compulsory wearing of seat belts in Australia: different trends between the sexes. Med J Aust 1979;2:571-5.
- 9. Paulson JA. The case for mandatory seat restraint laws. Clin Pediatr 1981; 20:285-90.
- Alcohol, Drug Abuse, and Mental Health Administration. Third special report to the U.S. Congress on alcohol and health. June 1978.
- 11. Skegg DCG, Richards SM, Doll R. Minor tranquilizers and road accidents. Br Med J 1979; 1:917.
- 12. Douglass RL, Millar CW. Alcohol availability and alcohol-related casualities in Michigan 1968-1976. Curr Alcohol 1979;6:303-17.
- Motorcycle Industry Council. State motorcycle equipment requirements. Washington, D.C.: Government Relations Office, January 1982.
- 14. National Safety Council. Accident Facts, 1981. Chicago: National Safety Council, 1981.
- 15. Carr WP, Brandt D, Swanson K. Injury patterns and helmet effectiveness among hospitalized motorcyclists. Minn Med 1981;64:521-7.
- Robertson LS. Crash involvement of teenage drivers when driver education is eliminated from high school. Am J Public Health 1980;70:599-603.

The Morbidity and Mortality Weekly Report, circulation 111,104, is published by the Centers for Disease Control, Atlanta, Georgia. The data in this report are provisional, based on weekly telegraphs to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday.

The editor welcomes accounts on interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Send reports to: Attn: Editor, Morbidity and Mortality Weekly Report, Centers for Disease Control, Atlanta, Georgia 30333.

Vol. 31/No. 35

MMWR

Subscription to MMWR

As announced in previous issues of the *MMWR*, the *MMWR* and its allied publications will become available on a paid subscription basis on October 1, 1982. A limited number of health officials and disseminators of public health information will continue to receive these publications without charge. Such officials are now being notified.

Subscribers who do not fall into the above categories may continue their subscriptions to the *MMWR* and its allied publications using either of the options described below.

1. Pre-publication subscription rate. Receipt of the completed form below by the National Technical Information Service (NTIS) on or before October 31, 1982, qualifies the subscriber for the pre-publication price of \$55 domestic (United States, Canada, and Mexico) (1st class mail will cost \$75.) and \$130 foreign (airmail letter will cost \$145). This option includes the weekly *MMWR* for 1 year, the October 1982 Quarterly Surveillance Report, and succeeding four Quarterly Surveillance Reports for the next year, the 1981 *MMWR* Annual Summary, and the 1982 *MMWR* Annual Summary.

2. Regular subscription rate. Subscriptions received after October 31, 1982, will be \$70 (domestic) (1st class mail will cost \$90.) and \$140 foreign (airmail letter will cost \$155) and will include the weekly *MMWR* for 1 year, the four Quarterly Surveillance Reports, and the 1982 *MMWR* Annual Summary.

	Domestic Price*	Foreign Price	Total Price
	3rd Class Mail	Airmail Printed Matter	
Number of subscriptions	\$55.00	\$130.00	
	Domestic Price*	Foreign Price	
	1st Class Mail	Airmail Letter	
Number of subscriptions	\$75.00	\$145.00	

*Includes United States, Canada, and Mexico.

These pre-publication prices apply if this form is *received* by October 31, 1982, after which the domestic price is \$70.00 (third class) and \$90.00 (first class) and the foreign price is \$140 (airmail printed matter) and \$155 (airmail letter).

THIS FORM CONTINUES ON THE NEXT PAGE

METHOD	OF PAYMENT
--------	-------------------

Enclosed: ()Check (U.S. dollars, drawn on a U.S. bank)() AmerEx () VISA () MasterCard
() Money Order (U.S. dollars, drawn on a U.S. bank) Number
() Charge my National Technical Information Service
Deposit Account Number Expiration Date
Signature (Required on all charge card orders)

() Check if address change is needed.

Make all changes on address label below.

SEND PAYMENT WITH ADDRESS LABEL TO: National Technical Information Service 5282 Port Royal Road Springfield, Virginia 22161

U.S. DEPARTMENT OF HEALTH AND HUMAN SERV PUBLIC HEALTH SERVICE / CENTERS FOR DISEAS ATLANTA, GEORGIA 30333		
OFFICIAL BUSINESS		
Director, Centers for Disease Control William H. Foege, M.D. Director, Epidemiology Program Office Phillip S. Brachman, M.D. Editor Michael B. Gregg, M.D. Mathematical Statistician Keewhan S 6HCRH3MCDJ73 8129 JOSEPH MC DADE PHD LEGIONNAIRE ACTIVITY LEPROSY & RICKETTSIA VIROLOGY DIV, CID 7-B5	Postage and Fees Paid U.S. Department of HHS HHS 396 211 L BR	LIS.MAIL